IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway

Circulation Journal

Volumn 72, Issue 3, 2008, Pages 469-475

  Nishimura, Yuki ^a   Nitto, Takeaki ^a   Inoue, Teruo ^a   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Endothelial cell; Interleukin 13; JAK2; STAT6

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; JANUS KINASE 2; STAT6 PROTEIN;

ANGIOGENESIS; ARTICLE; CAPILLARY; CELL MIGRATION; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN FUNCTION; RNA INTERFERENCE; VASCULAR ENDOTHELIUM;

CELL MOVEMENT; CELLS, CULTURED; CORONARY VESSELS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; JANUS KINASE 2; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-4; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR;

EID: 42649145091     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.469     Document Type: Article

References (36)

1. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM, Zhu Z, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002; 8: 885-889.
2. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: Central mediator of allergic asthma. Science 1998; 282: 2258-2261.
3. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550-564.
4. Kolios G, Rooney N, Murphy CT, Robertson DA, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: Modulation by T lymphocyte derived cytokines. Gut 1998; 43: 56-63.
5. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000; 164: 2585-2591.
6. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245-248.
7. McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, Zurauski G, et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998; 9: 423-432.
8. McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie NJ. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999; 189: 1565-1572.
9. Brombacher F. The role of interleukin-13 in infectious diseases and allergy. BioEssays 2000; 22: 646-656.
10. Hershey GK. IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol 2003; 111: 677-691.
11. Aman MJ, Tayebi N, Obiri NI, Purr RK, Modi WS, Leonard WJ. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem 1996; 271: 29265-29270.
12. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, et al. The murine IL-13 receptor α2: Molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 1998; 161: 2317-2324.
13. Palmer-Crocker RL, Hughes CC, Pober JS. IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the γc chain. J Clin Invest 1996; 98: 604-609.
14. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380: 630-633.
15. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996; 157: 3220-3222.
16. Mascareno E, El-Shafei M, Maulik N, Sato M, Guo Y, Das DK, et al. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 2001; 104: 325-329.
17. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA. Stat6 activation is essential for interleukin-4 induction of P-selectin transcription in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1421-1429.
18. Kotowicz K, Callard RE, Friedrich K, Matthews DJ, Klein N. Biological activity of IL-4 and IL-13 on human endothelial cells: Functional evidence that both cytokines act through the same receptor. Int Immunol 1996; 8: 1915-1925.
19. Schnyder B, Lugli S, Feng N, Etter H, Lutz RA, Ryffel B, et al. Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common γ chain. Blood 1996; 87: 4286-4295.
20. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.
21. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
22. Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998; 188: 1039-1046.
23. Lauder H, Frost EE, Hiley CR, Fan TP. Quantification of the repair process involved in the repair of a cell monolayer using an in vitro model of mechanical injury. Angiogenesis 1998; 2: 67-80.
24. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, et al. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix: Role of urokinase activity. J Cell Biol 1996; 132: 1177-1188.
25. Fukushi J, Morisaki T, Shono T, Nishie A, Torisu H, Ono M, et al. Novel biological functions of interleukin-4: Formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem Biophys Res Commun 1998; 250: 444-448.
26. Fukushi J, Ono M, Morikawa W, Iwamoto Y, Kuwano M. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J Immunol 2000; 165: 2818-2823.
27. Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK 3rd, Woods JM, et al. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 2006; 54: 2402-2414.
28. Nishimura Y, Nitto T, Inoue T, Node K. STAT6 mediates apoptosis of human coronary arterial endothelial cells by IL-13. Hypertension Res 2007 (in press).
29. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988; 107: 1589-1598.
30. Hamano Y, Kalluri R. Tumstatin, the NC1 domain of α3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun 2005; 333: 292-298.
31. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin's molecular mechanism: Aspects of specificity and regulation elucidated. J Cell Biochem 2005; 96: 242-261.
32. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-6628.
33. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
34. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, et al. TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism. Cell 2003; 114: 171-180.
35. Nishimura Y, Inoue T, Nitto T, Morooka T, Node K. Increased Interleukin-13 levels in patients with chronic heart failure. Int J Cardiol 2007 (in press).
36. Foteinos G, Afzal AR, Mandal K, Jahangiri M, Xu Q. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 2005; 112: 1206-1213.